$VSEE
VSEE HEALTH, INC. Stock $vsee

$vsee Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000110465924046607 Filed on April 12, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$1.712M	$0.00	$0.00
YoY Change
Cost Of Revenue	$486.6K
YoY Change	2.6%
Gross Profit	$1.225M
YoY Change	50.13%
Gross Profit Margin	71.57%
Selling, General & Admin		$925.7K	$2.594M
YoY Change		-22.88%	-27.85%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.473K
YoY Change	838.22%
% of Gross Profit	0.12%
Operating Expenses	$2.408M	$925.7K	$2.594M
YoY Change	444.33%	-22.88%	-27.85%
Operating Profit	-$1.183M		-$2.594M
YoY Change	167.46%		-27.85%
Interest Expense		-$1.642M	-$1.527M
YoY Change		-2461.59%	-382.93%
% of Operating Profit
Other Income/Expense, Net	-$1.420M	-$293.2K	-$293.2K
YoY Change	-301.11%		-154.32%
Pretax Income	-$2.603M	-$2.861M	-$4.414M
YoY Change	-1087.73%	153.03%	44.47%
Income Tax	-$2.241M	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$330.0K	-$2.861M	-$4.414M
YoY Change	-225.21%	131.68%	36.13%
Net Earnings / Revenue	-19.28%
Basic Earnings Per Share	-$0.06		-$1.08
Diluted Earnings Per Share	-$0.06	-$0.74	-$1.08
COMMON SHARES
Basic Shares Outstanding	3.604M	3.584M	4.096M
Diluted Shares Outstanding	5.302M		4.096M

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.860K	$1.860K
YoY Change		-98.26%	-98.26%
Cash & Equivalents	$1.106M	$1.863K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$2.514M	$628.5K
Other Receivables	$785.9K
Total Short-Term Assets	$5.167M	$1.860K	$1.860K
YoY Change	7744.63%	-98.26%	-98.26%
LONG-TERM ASSETS
Property, Plant & Equipment	$883.3K	$3.657K
YoY Change
Goodwill	$59.90M
YoY Change
Intangibles	$12.10M
YoY Change
Long-Term Investments		$1.369M	$1.369M
YoY Change		-81.82%	-81.82%
Other Assets
YoY Change
Total Long-Term Assets	$73.82M	$1.369M	$1.369M
YoY Change	821.01%	-81.82%	-81.82%
TOTAL ASSETS
Total Short-Term Assets	$5.167M	$1.860K	$1.860K
Total Long-Term Assets	$73.82M	$1.369M	$1.369M
Total Assets	$78.99M	$1.371M	$1.371M
YoY Change	877.44%	-82.05%	-82.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$3.304M	$3.304M
YoY Change		75.15%	75.15%
Accrued Expenses		$96.36K	$96.36K
YoY Change		128.34%
Deferred Revenue	$1.023M	$802.5K
YoY Change
Short-Term Debt		$1.549M	$1.549M
YoY Change		125.55%	125.55%
Long-Term Debt Due	$928.3K	$220.0K
YoY Change
Total Short-Term Liabilities	$22.88M	$7.984M	$7.984M
YoY Change	353.63%	142.27%	142.27%
LONG-TERM LIABILITIES
Long-Term Debt	$593.9K	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$4.370M	$4.370M
YoY Change		0.0%	0.0%
Total Long-Term Liabilities	$593.9K	$4.370M	$4.370M
YoY Change	-86.41%	0.0%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$22.88M	$7.984M	$7.984M
Total Long-Term Liabilities	$593.9K	$4.370M	$4.370M
Total Liabilities	$24.18M	$12.35M	$12.35M
YoY Change	156.83%	61.17%	61.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$9.773M	-$12.82M
YoY Change	0.19%	66.02%
Common Stock	$1.481K	$350.00
YoY Change		0.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		-$10.98M	-$10.98M
YoY Change
Total Liabilities & Shareholders Equity	$78.99M	$1.371M	$1.371M
YoY Change	877.44%	-82.05%	-82.05%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$330.0K	-$2.861M	-$4.414M
YoY Change	-225.21%	131.68%	36.13%
Depreciation, Depletion And Amortization	$1.473K
YoY Change	838.22%
Cash From Operating Activities		-$321.5K	-$962.0K
YoY Change		-52.46%	-30.85%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$6.808M	$6.518M
YoY Change		-93.82%	-94.08%
Cash From Investing Activities		$6.808M	$6.518M
YoY Change		-93.82%	-94.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$6.796M
YoY Change			-106.15%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-6.485M	-5.661M
YoY Change		-94.07%	-94.83%
NET CHANGE
Cash From Operating Activities		-321.5K	-962.0K
Cash From Investing Activities		6.808M	6.518M
Cash From Financing Activities		-6.485M	-5.661M
Net Change In Cash		1.360K	-105.1K
YoY Change		-97.81%	-83.9%
FREE CASH FLOW
Cash From Operating Activities		-$321.5K	-$962.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001864531
CY2022Q4	dhacu	Fair Value Liabilities Level2 To Level1 Transfer Amount FairValueLiabilitiesLevel2ToLevel1TransferAmount	0
CY2023Q4	dhacu	Fair Value Liabilities Level2 To Level1 Transfer Amount FairValueLiabilitiesLevel2ToLevel1TransferAmount	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3	0
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3 FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3	0
CY2023	dei	Entity File Number EntityFileNumber	001-41015
CY2022Q4	us-gaap	Other Liability Current Related Party Type Extensible Enumeration OtherLiabilityCurrentRelatedPartyTypeExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	dhacu	Extension Period To Consummate Business Combination ExtensionPeriodToConsummateBusinessCombination	P3M
CY2022Q4	dhacu	Maximum Extension Period To Consummate Business Combination MaximumExtensionPeriodToConsummateBusinessCombination	P9M
CY2023Q4	dhacu	Extension Fee If Form S4 Registration Statement Is Filed ExtensionFeeIfFormS4RegistrationStatementIsFiled	P3M
CY2023Q4	dhacu	Maximum Extension Period To Consummate Business Combination MaximumExtensionPeriodToConsummateBusinessCombination	P3M
CY2023Q4	dhacu	Extension Period To Consummate Business Combination ExtensionPeriodToConsummateBusinessCombination	P3M
CY2023Q4	dhacu	Maximum Extension Period To Consummate Business Combination MaximumExtensionPeriodToConsummateBusinessCombination	P12M
CY2023Q4	dhacu	Extension Period To Consummate Business Combination ExtensionPeriodToConsummateBusinessCombination	P3M
CY2023Q4	dhacu	Maximum Extension Period To Consummate Business Combination MaximumExtensionPeriodToConsummateBusinessCombination	P12M
CY2023	dhacu	Redemption Of Shares Calculated Based On Number Of Business Days Prior To Consummation Of Business Combination RedemptionOfSharesCalculatedBasedOnNumberOfBusinessDaysPriorToConsummationOfBusinessCombination	P2D
CY2023	dhacu	Redemption Period Upon Closure RedemptionPeriodUponClosure	P10D
CY2023Q4	dhacu	Shares Agreed To Be Purchased Period SharesAgreedToBePurchasedPeriod	P36M
CY2023	dhacu	Redemption Period Upon Closure RedemptionPeriodUponClosure	P10D
CY2023	dhacu	Warrant Exercise Period Condition One WarrantExercisePeriodConditionOne	P30D
CY2023	dhacu	Warrant Exercise Period Condition Two WarrantExercisePeriodConditionTwo	P12M
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	DIGITAL HEALTH ACQUISITION CORP.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2970927
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	980 N Federal Hwy #304
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33432
CY2023	dei	City Area Code CityAreaCode	561
CY2023	dei	Local Phone Number LocalPhoneNumber	672-7068
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2023Q2	dei	Entity Public Float EntityPublicFloat	8750583
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3603966
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	WithumSmith+Brown, PC
CY2023	dei	Auditor Location AuditorLocation	New York, New York
CY2023	dei	Auditor Firm AuditorFirmId	100
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1863
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	106998
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1863
CY2022Q4	us-gaap	Assets Current AssetsCurrent	106998
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	1368637
CY2022Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	7527369
CY2023Q4	us-gaap	Assets Assets	1370500
CY2022Q4	us-gaap	Assets Assets	7634367
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	3303836
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1886312
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	72396
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	187225
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	187225
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	117871
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	43900
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	23964
CY2023Q4	dhacu	Promissory Note Related Party Classified Current PromissoryNoteRelatedPartyClassifiedCurrent	926500
CY2022Q4	dhacu	Promissory Note Related Party Classified Current PromissoryNoteRelatedPartyClassifiedCurrent	350000
CY2022Q4	dhacu	Pipe Forward Contract Derivative PipeForwardContractDerivative	170666
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	7984400
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3295614
CY2023Q4	dhacu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	4370000
CY2022Q4	dhacu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	4370000
CY2023Q4	us-gaap	Liabilities Liabilities	12354400
CY2022Q4	us-gaap	Liabilities Liabilities	7665614
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	1281957
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	7395349
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	350
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	347
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	550246
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	292973
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12816453
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7719916
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-12265857
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7426596
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1370500
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7634367
CY2023	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	2593765
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	3594967
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2593765
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3594967
CY2023	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	-170666
CY2022	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	170666
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	358767
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	922644
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1820101
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	539691
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4413866
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3055276
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	187225
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4413866
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3242501
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4096353
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4096353
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12741219
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12741219
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-3334468
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	1142603
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3242501
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-7426596
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	214200
CY2023	dhacu	Adjustments To Additional Paid In Capital Excise Tax On Redemption AdjustmentsToAdditionalPaidInCapitalExciseTaxOnRedemption	72396
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	682671
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4413866
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-12265857
CY2023	us-gaap	Profit Loss ProfitLoss	-4413866
CY2022	us-gaap	Profit Loss ProfitLoss	-3242501
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	358767
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	922644
CY2023	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	-170666
CY2022	dhacu	Change In Fair Value Of Pipe Forward Contract Derivative ChangeInFairValueOfPipeForwardContractDerivative	170666
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-457605
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1631724
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1746149
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	187225
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-962042
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1391213
CY2023	dhacu	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	350000
CY2022	dhacu	Payments For Investment Of Cash In Trust Account PaymentsForInvestmentOfCashInTrustAccount	350000
CY2023	dhacu	Proceeds Of Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes ProceedsOfCashWithdrawnFromTrustAccountToPayFranchiseAndIncomeTaxes	71436
CY2022	dhacu	Proceeds Of Cash Withdrawn From Trust Account To Pay Franchise And Income Taxes ProceedsOfCashWithdrawnFromTrustAccountToPayFranchiseAndIncomeTaxes	110472253
CY2023	dhacu	Proceeds From Trust Account In Connection With Redemptions ProceedsFromTrustAccountInConnectionWithRedemptions	6796063
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6517499
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	110122253
CY2023	dhacu	Proceeds From Related Party As Advances ProceedsFromRelatedPartyAsAdvances	95037
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	21066
CY2023	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	100000
CY2022	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	800000
CY2023	dhacu	Proceeds From M2b Note ProceedsFromM2bNote	145000
CY2022	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	61800
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	576500
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	350000
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	240000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	6796063
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	110472254
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5660592
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-109384054
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-105135
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-653014
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106998
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	760012
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1863
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	106998
CY2023	us-gaap	Stock Issued1 StockIssued1	214200
CY2022	us-gaap	Stock Issued1 StockIssued1	284424
CY2023	dhacu	Embedded Derivative Bridge Note Settlement With Exchange Note EmbeddedDerivativeBridgeNoteSettlementWithExchangeNote	244444
CY2023	dhacu	Excise Tax On Redemption Of Common Stock ExciseTaxOnRedemptionOfCommonStock	72396
CY2023	dhacu	Common Stock Issued As Financing Cost In Note CommonStockIssuedAsFinancingCostInNote	78349
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NOTE 1. DESCRIPTION OF ORGANIZATION AND BUSINESS OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Digital Health Acquisition Corp. (the “Company” or “DHAC”) is a blank check company incorporated as a Delaware corporation on March 30, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar Business Combination with one or more businesses (the “Business Combination”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 9, 2022, DHAC Merger Sub I, Inc. (“Merger Sub I”), a Delaware corporation and a wholly owned subsidiary of the Company, was formed. On June 9, 2022, DHAC Merger Sub II, Inc. (“Merger Sub II”), a Texas corporation and a wholly owned subsidiary of the Company, was formed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December 31, 2023, the Company had not commenced any significant operations. All activity for the period from inception, the date which operations commenced, through December 31, 2023 relates to the Company’s formation, the Company’s Initial Public Offering (as defined below), and identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income from the proceeds derived from the Initial Public Offering (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The registration statement for the Company’s Initial Public Offering was declared effective on November 3, 2021. On November 8, 2021, the Company consummated the Initial Public Offering of 11,500,000 units (the “Units” and, with respect to the shares of common stock included in the Units sold, the “Public Shares”), which includes the full exercise by the underwriter of its over-allotment option in the amount of 1,500,000 Units, at $10.00 per Unit, generating gross proceeds of $115,000,000, which is described in Note 3. On October 20, 2022, in connection with the stockholders meeting to approve the extension, 10,805,877 shares of DHAC’s common stock were redeemed leaving 694,123 shares of common stock subject to redemption. On November 6, 2023, in connection with the stockholders meeting to approve the extension, 579,157 shares of DHAC’s common stock were redeemed leaving 114,966 shares of common stock subject to redemption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Simultaneously with the closing of the Initial Public Offering, the Company consummated the sale of 557,000 units (each, a “Private Placement Unit” and, collectively, the “Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to Digital Health Sponsor LLC (the “Sponsor”), generating gross proceeds of $5,570,000, which is described in Note 4. As of November 8, 2021, the Company received $3,680,000 from the proceeds of the Private Placement and recorded $1,890,000 in subscription receivable. The Sponsor paid the subscription in full on November 12, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transaction costs amounted to $6,877,164, consisting of $1,955,000 of underwriting fees, $4,370,000 of deferred underwriting fees and $552,164 of other offering costs. In addition, cash of $9,478 was held outside of the Trust Account (as defined below) and is available for the payment of offering costs and for working capital purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the closing of the Initial Public Offering on November 8, 2021, an amount of $116,725,000 ($10.15 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private Placement Units was placed in a trust account (the “Trust Account”), invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in any open-ended investment company that holds itself out as a money market fund meeting the conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Trust Account is intended as a holding place for funds pending the earliest to occur of either (i) the completion of the initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Company’s public shares if the Company does not complete the initial Business Combination within 27 months from the closing of the Initial Public Offering (as extended as of December 31, 2023) or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity; or (iii) absent an initial Business Combination within 27 months from the closing of the Initial Public Offering (as extended as of December 31, 2023), the Company’s return of the funds held in the Trust Account to the Company’s public stockholders as part of the Company’s redemption of the public shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 20, 2022, stockholders of DHAC approved a proposal to amend DHAC’s amended and restated certificate of incorporation to (a) extend the date by which DHAC has to consummate a Business Combination (the “Extension”) for an additional <span style="-sec-ix-hidden:Hidden_Hp5y9HUEqkuTYdk3jV-20Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, from November 8, 2022 to February 8, 2023, (b) provide DHAC’s board of directors the ability to further extend the date by which DHAC has to consummate a Business Combination up to three (3) additional times for three (3) months each time, for a maximum of <span style="-sec-ix-hidden:Hidden_fVrViMIfkk6CNPv31WxnQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nine</span></span> (9) additional months if the Sponsor pays an amount equal to $350,000 for each three-month extension (the “Extension Fee”), </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">which amount shall be deposited in the trust account of DHAC; provided, that if as of the time of an extension DHAC has filed a Form S-4 registration statement in connection with its initial Business Combination, then no Extension Fee would be required in connection with such extension; provided further that for each <span style="-sec-ix-hidden:Hidden_N00xuUBdIkaii50lk1QdWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span>–month extension (if any) following such extension where no deposit into the Trust Account or other payment has been made, an Extension Fee is required, and (c) allow for DHAC to provide redemption rights to DHAC’s public stockholders in accordance with the requirements of the amended and restated certificate of incorporation without complying with the tender offer rules. In connection with such stockholder vote, an aggregate of 10,805,877 shares of DHAC’s common stock were redeemed leaving 4,156,123 shares issued and outstanding and entitled to vote as of October 20, 2022. The Company subsequently extended the date by which the Company has to consummate a Business Combination pursuant to the three additional <span style="-sec-ix-hidden:Hidden_q066_Eb1AUmc_XxVkEhU_w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> – month extensions to November 8, 2023, and deposited an aggregate of $700,000 into the Trust Account as extension fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 8, 2023, DHAC held a Special Meeting and the stockholders approved an amendment of the Company’s amended and restated certificate of incorporation (as amended from time to time, the “Charter”) to expand the methods that the Company may employ to not become subject to the “penny stock” rules of the U.S. Securities and Exchange Commission (“SEC”). On September 8, 2023, DHAC filed such amendment, which provided that DHAC would be able to consummate the Business Combination even if as a result of the transactions the combined company does not have net tangible assets of at least $5,000,001 upon consummation of such business combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 6, 2023, DHAC held its 2023 annual stockholders meeting (“2023 Annual Meeting”). At the 2023 Annual Meeting, the stockholders of DHAC approved amendments to DHAC’s Charter to extend the date by which the Company must consummate a Business Combination (as defined in the Charter) up to four (4) times, each by an additional <span style="-sec-ix-hidden:Hidden_BO2XB4KTckiTwT9QBrFZBQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, for an aggregate of <span style="-sec-ix-hidden:Hidden_cesckZLqaUGtBDxTt5Sc7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span> (12) additional months (i.e., from November 8, 2023 up to November 8, 2024) or such earlier date as determined by the Company’s board of directors. In connection with the amended Charter, on November 6, 2023, DHAC extended the period of time that it has to consummate its business combination by three months from November 8, 2023 to February 8, 2024. In addition, on February 2, 2024, DHAC further extended the period of time that it has to consummate its business combination by another three months from February 8, 2024 to May 8, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Furthermore, at the 2023 Annual Meeting, the stockholders of DHAC also approved an amendment to DHAC’s investment management trust agreement (the “Trust Agreement”), dated as of November 3, 2021 and as amended on October 26, 2022, by and between the Company and Continental Stock Transfer & Trust Company, which allows the Company to extend the business combination period from November 8, 2023 to up to four (4) times, each by an additional <span style="-sec-ix-hidden:Hidden_bN0oXxJn8kKBfNtRJKRPOA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> (3) months, for an aggregate of <span style="-sec-ix-hidden:Hidden_qi-WHydKhUul4xxhD616rA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twelve</span></span> (12) additional months to November 8, 2024 (the “Combination Period”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the 2023 Annual Meeting and amendments to DHAC’s Charter and Trust Agreement, 579,157 shares of Common Stock were redeemed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Business Combination must be with one or more target businesses that together have a fair market value equal to at least 80% of the net balance in the Trust Account (as defined below) (excluding the amount of deferred underwriting discounts held and taxes payable on the income earned on the Trust Account) at the time of the signing an agreement to enter into a Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect a Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company will provide the Company’s public stockholders with the opportunity to redeem all or a portion of their common shares in connection with the initial Business Combination either (i) in connection with a general meeting called to approve the Business Combination or (ii) without a stockholder vote by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Business Combination or conduct a tender offer will be made by the Company, solely in its discretion, and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would require the Company to seek stockholder approval under applicable law or stock exchange listing requirement. The public stockholders will be entitled to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of <span style="-sec-ix-hidden:Hidden_UN8F2ARF0U6gyglBHypfzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> business days prior to the consummation of the initial Business Combination, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes, divided by the number of then outstanding public shares, subject to the limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Company is unable to complete its initial Business Combination within the Combination Period, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than <span style="-sec-ix-hidden:Hidden_FGCraKyGdkaZxGkzVGTMNQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders (including the right to receive further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the Company’s remaining stockholders and the Company’s board of directors, liquidate and dissolve, subject, in each case, to the Company’s obligations under Delaware law to provide for claims of creditors and in all cases subject to the other requirements of applicable law. The shares of common stock subject to redemption are recorded at a redemption value and classified as temporary equity in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 480, “Distinguishing Liabilities from Equity”.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sponsor, along with certain advisors, officers and directors, has entered into a letter agreement with the Company, pursuant to which they have agreed to (i) waive their redemption rights with respect to their founder shares (as defined in Note 5) and public shares in connection with the completion of the initial Business Combination; (ii) waive their redemption rights with respect to their founder shares and public shares in connection with a stockholder vote to approve an amendment to the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s obligation to allow redemption in connection with the initial Business Combination or to redeem 100% of the Company’s public shares. If the Company have not consummated an initial Business Combination within the Combination Period or (B) with respect to any other material provisions relating to stockholders’ rights or pre-initial Business Combination activity; (iii) waive their rights to liquidating distributions from the Trust Account with respect to their founder shares if the Company fails to complete the initial Business Combination within the Combination Period, although they will be entitled to liquidating distributions from the Trust Account with respect to any public shares they hold if the Company fails to complete the initial Business Combination within the prescribed time frame; and (iv) vote any founder shares held by them and any public shares purchased during or after the Initial Public Offering (including in open market and privately negotiated transactions) in favor of the initial Business Combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company have entered into a written letter of intent, confidentiality or other similar agreement or Business Combination agreement, reduce the amount of funds in the Trust Account to below the lesser of (i) $10.15 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.15 per share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked the Sponsor to reserve for such indemnification obligations, nor have the Company independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and the Company believes that the Company’s Sponsor’s only assets are securities of the Company. Therefore, the Company cannot assure that the Sponsor would be able to satisfy those obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 15, 2022, DHAC entered into the original Business Combination Agreement, by and among DHAC, DHAC Merger Sub I, Inc. (“Merger Sub I”), DHAC Merger Sub II, Inc. (“Merger Sub II” and together with Merger Sub I, the “Merger Subs”), VSee Lab, Inc., a Delaware corporation (“VSee”), and iDoc Virtual Telehealth Solutions, Inc., a Texas corporation (“iDoc”). On August 9, 2022, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into the First Amended and Restated Business Combination Agreement to provide for the concurrent execution of financing documents for a PIPE financing consisting of convertible notes and warrants and delivery of the Cassel Salpeter’s opinion to the Board. On October 6, 2022, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into a Second Amended and Restated Business Combination Agreement to make the consideration payable to VSee and iDoc stockholders 100% DHAC common stock and to provide for the concurrent execution of amended PIPE financing documents providing for the issuance of the shares and warrants to the PIPE investors. On November 3, 2022, the parties entered into a First Amendment to the Second Amended and Restated Business Combination Agreement to remove a closing condition that DHAC have at least $10 million in cash proceeds from the transactions at closing. On July 11, 2023, each of the PIPE Investors provided notice to the Company that since a closing condition was not met, the PIPE Investors were under no obligation to close the PIPE Financing. Accordingly, the PIPE financing was terminated. On November 21, 2023, DHAC, Merger Sub I, Merger Sub II, VSee and iDoc entered into the Third Amended and Restated Business Combination Agreement (as amended and restated, the “Business Combination Agreement” and the transactions contemplated thereby, the “Business Combination”) to, among other things, provide for the removal of the PIPE financing and the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">concurrent execution of the Additional Bridge Financing, the Exchange Financing, the Quantum Financing, the Equity Financing and the Loan Conversions, which are described in Note 6 – Commitments. The DHAC Board has (i) approved and declared advisable the Business Combination Agreement, the Business Combination and the other transactions contemplated thereby and (ii) resolved to recommend approval of the Business Combination Agreement and related matters by the stockholders of DHAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Business Combination Agreement and subject to the terms and conditions set forth therein, Merger Sub I will merge with and into VSee (the “VSee Merger”), with VSee surviving the VSee Merger as a wholly owned subsidiary of DHAC, and Merger Sub II will merge with and into iDoc (the “iDoc Merger” and, together with the VSee Merger, the “Mergers”), with iDoc surviving the iDoc Merger as a wholly owned subsidiary of DHAC. At the effective time of the Mergers (the “Effective Time”), DHAC will change its name to VSee Health, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NASDAQ Trading Status</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, DHAC received a letter from the staff (the “Staff”) at The Nasdaq Global Market (“Nasdaq Global”) notifying DHAC that for the 30 consecutive trading days prior to the date of the Letter, DHAC’s securities listed on the Nasdaq Global (including the Common Stock, Units and Warrants) (the “Securities”) had traded at a value below the minimum $50,000,000 “Market Value of Listed Securities (“MVLS”) requirement set forth in Nasdaq Listing Rule 5450(b)(2)(A), which is required for continued listing of DHAC’s Securities on Nasdaq Global. In accordance with Nasdaq listing rule 5810I(3)I, DHAC had 180 calendar days, or until September 27, 2023, to regain compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 23, 2023, DHAC received a second letter from the Staff notifying DHAC that for the prior 30 consecutive business days, DHAC’s market value of publicly held shares (“MVPHS”) was below the $15 million required for continued listing on the Nasdaq Global and therefore, DHAC no longer met Nasdaq Listing Rule 5450(b)(3)(C) (the “MVPHS Requirement”). In accordance with Nasdaq Listing Rule 5810I(3)(D), DHAC had 180 calendar days, or until November 20, 2023, to regain compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 28, 2023, DHAC received a third letter from the Staff notifying DHAC that the Staff had determined to delist DHAC’s Securities because it had not regained compliance with the MVLS standard. Pursuant to the third letter, on October 4, 2023, DHAC requested a hearing (the “Hearing”) to appeal this determination and also applied to transfer the listing of its Securities from Nasdaq Global to the Nasdaq Capital Market (“NasdaqCM”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 9, 2023, DHAC received a fourth letter from the Staff notifying DHAC that its not meeting the 400 total shareholders requirement under the Nasdaq Listing Rule 5450(a)(2) served as an additional basis for delisting DHAC’s Securities from Nasdaq Global.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 26, 2023, the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market notified DHAC in writing (the “Notice”) that its application to transfer the listing of its Securities to NasdaqCM had been approved. DHAC’s Securities were transferred to the NasdaqCM at the opening of business on October 30, 2023. On November 1, 2023, DHAC received a letter from the Nasdaq Global Hearing panel that due to DHAC’s transfer of its listed Securities to NasdaqCM, the Hearing on November 30, 2023 regarding non-compliance with the Nasdaq Global listing standards had been cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of October 30, 2023, DHAC’s Securities are listed and traded on The Nasdaq Stock Market on NasdaqCM and will continue to be listed and traded on NasdaqCM.</p>
CY2023	dhacu	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
CY2023Q4	dhacu	Transaction Costs TransactionCosts	6877164
CY2023Q4	dhacu	Sale Of Stock Underwriting Fees SaleOfStockUnderwritingFees	1955000
CY2023Q4	dhacu	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	4370000
CY2023Q4	dhacu	Sale Of Stock Other Offering Costs SaleOfStockOtherOfferingCosts	552164
CY2023Q4	dhacu	Cash Held Outside Trust Account CashHeldOutsideTrustAccount	9478
CY2022Q4	dhacu	Number Of Extensions To Consummate Business Combination NumberOfExtensionsToConsummateBusinessCombination	3
CY2022Q4	dhacu	Extension Fee Payable By Sponsor ExtensionFeePayableBySponsor	350000
CY2023Q4	dhacu	Extension Fee For Each Additional Three Months Extension Period ExtensionFeeForEachAdditionalThreeMonthsExtensionPeriod	0
CY2023Q4	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	10805877
CY2023Q4	dhacu	Shares Issued And Outstanding Entitled To Vote SharesIssuedAndOutstandingEntitledToVote	4156123
CY2023Q4	dhacu	Number Of Extensions To Consummate Business Combination NumberOfExtensionsToConsummateBusinessCombination	3
CY2023Q4	dhacu	Aggregate Amount Deposited Into Trust Account As Extension Fees AggregateAmountDepositedIntoTrustAccountAsExtensionFees	700000
CY2023Q3	dhacu	Condition For Future Business Combination Threshold Net Tangible Assets ConditionForFutureBusinessCombinationThresholdNetTangibleAssets	5000001
CY2023Q4	dhacu	Number Of Extensions To Consummate Business Combination NumberOfExtensionsToConsummateBusinessCombination	4
CY2023Q4	dhacu	Term By Which Period To Consummate Initial Business Combination Extended TermByWhichPeriodToConsummateInitialBusinessCombinationExtended	P3M
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2023Q4	dhacu	Number Of Extensions To Consummate Business Combination NumberOfExtensionsToConsummateBusinessCombination	4
CY2023	dhacu	Condition For Future Business Combination Number Of Businesses Minimum ConditionForFutureBusinessCombinationNumberOfBusinessesMinimum	1
CY2023	dhacu	Threshold Minimum Aggregate Fair Market Value As Percentage Of Asset Held In Trust Account ThresholdMinimumAggregateFairMarketValueAsPercentageOfAssetHeldInTrustAccount	80
CY2023	dhacu	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	50
CY2023	dhacu	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000
CY2022Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	10000000
CY2023	dhacu	Threshold Consecutive Trading Days Prior To Date Of Letter ThresholdConsecutiveTradingDaysPriorToDateOfLetter	P30D
CY2023Q1	dhacu	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	50000000
CY2023Q2	dhacu	Threshold Consecutive Trading Days Prior To Date Of Letter ThresholdConsecutiveTradingDaysPriorToDateOfLetter	P30D
CY2023Q2	dhacu	Minimum Market Value Of Listed Securities MinimumMarketValueOfListedSecurities	15000000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1863
CY2023	dhacu	Working Capital WorkingCapital	7982537
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. The most significant accounting estimates were the assumptions used to fair value the PIPE Forward Contract, the Extension Note Bifurcated Derivative, the Bridge Note Bifurcated Derivative, the Additional Bridge Note and the Exchange Note (each term as defined below). Accordingly, the actual results could differ significantly from those estimates.</p>
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.061
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4413866
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3242501
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4096353
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4096353
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12741219
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12741219
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.25
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.25
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The Company has significant cash balances at a financial institutions which throughout the year regularly exceeded the federally insured limited of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</span></p>
CY2023	dhacu	Percentage Of Common Stock Shares To Be Redeemed Or Repurchased Upon Failure To Consummate Business Combination PercentageOfCommonStockSharesToBeRedeemedOrRepurchasedUponFailureToConsummateBusinessCombination	1
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	72396
CY2023	dhacu	Proceeds Held In Trust Account Used To Repay Working Capital Loans ProceedsHeldInTrustAccountUsedToRepayWorkingCapitalLoans	0
CY2023Q4	dhacu	Maximum Value Of Shares Agreed To Be Purchased MaximumValueOfSharesAgreedToBePurchased	50000000
CY2021Q4	dhacu	Maximum Number Of Demands For Registration Of Securities MaximumNumberOfDemandsForRegistrationOfSecurities	2
CY2023	dhacu	Deferred Underwriting Commission Percent DeferredUnderwritingCommissionPercent	3.8
CY2023Q4	dhacu	Debt Instrument Convertible Stock Price Trigger For Reset Of Conversion Price DebtInstrumentConvertibleStockPriceTriggerForResetOfConversionPrice	3
CY2023Q4	dhacu	Maximum Consecutive Days For Suspension For Use Of Resale Registration Statement MaximumConsecutiveDaysForSuspensionForUseOfResaleRegistrationStatement	90
CY2023Q4	dhacu	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2023	dhacu	Months To Complete Acquisition Period MonthsToCompleteAcquisitionPeriod	P27M
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12057000
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	12057000
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023	dhacu	Number Of Warrants Exercisable For Cash NumberOfWarrantsExercisableForCash	0
CY2023	dhacu	Warrants Trading Days On Which Fair Market Value Of Shares Is Reported WarrantsTradingDaysOnWhichFairMarketValueOfSharesIsReported	5
CY2023	dhacu	Warrants Trading Days On Which Fair Market Value Of Shares Is Reported WarrantsTradingDaysOnWhichFairMarketValueOfSharesIsReported	5
CY2023Q4	dhacu	Share Price Trigger Used To Measure Dilution Of Warrants SharePriceTriggerUsedToMeasureDilutionOfWarrants	9.20
CY2023	dhacu	Percentage Of Gross New Proceeds To Total Equity Proceeds Used To Measure Dilution Of Warrant PercentageOfGrossNewProceedsToTotalEquityProceedsUsedToMeasureDilutionOfWarrant	60
CY2023Q4	dhacu	Share Price Trigger Used To Measure Dilution Of Warrants SharePriceTriggerUsedToMeasureDilutionOfWarrants	9.20
CY2023	dhacu	Warrant Exercise Price Adjustment Multiple WarrantExercisePriceAdjustmentMultiple	115
CY2023	dhacu	Warrant Redemption Condition Minimum Share Price WarrantRedemptionConditionMinimumSharePrice	18.00
CY2022	dhacu	Warrant Redemption Price Adjustment Multiple WarrantRedemptionPriceAdjustmentMultiple	180
CY2023Q4	dhacu	Common Stock Number Of Votes Per Share CommonStockNumberOfVotesPerShare	1
CY2023	dhacu	Warrant Exercise Restriction Threshold Percent Of Common Stock Owned WarrantExerciseRestrictionThresholdPercentOfCommonStockOwned	9.8
CY2023Q4	dhacu	Exercise Of Warrants Fractional Shares Issued ExerciseOfWarrantsFractionalSharesIssued	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	dhacu	Deferred Tax Assets Net Operating Loss Carryforwards DeferredTaxAssetsNetOperatingLossCarryforwards	461882
CY2022Q4	dhacu	Deferred Tax Assets Net Operating Loss Carryforwards DeferredTaxAssetsNetOperatingLossCarryforwards	-379
CY2023Q4	dhacu	Deferred Tax Assets Capitalized Start Up And Organization Costs DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts	1622610
CY2022Q4	dhacu	Deferred Tax Assets Capitalized Start Up And Organization Costs DeferredTaxAssetsCapitalizedStartUpAndOrganizationCosts	962297
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2084492
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	961918
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2084492
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	961918
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	187225
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-926728
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-741805
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-191524
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-153306
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1118252
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-895111
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	187225
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	1822738
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-1118252
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-895111
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.043
CY2023	dhacu	Effective Income Tax Rate Reconciliation Of Bridge Note Bifurcated Derivative EffectiveIncomeTaxRateReconciliationOfBridgeNoteBifurcatedDerivative	0.007
CY2022	dhacu	Effective Income Tax Rate Reconciliation Of Bridge Note Bifurcated Derivative EffectiveIncomeTaxRateReconciliationOfBridgeNoteBifurcatedDerivative	-0.007
CY2023	dhacu	Effective Income Tax Rate Reconciliation Of Pipe Forward Contract Derivative EffectiveIncomeTaxRateReconciliationOfPipeForwardContractDerivative	0.010
CY2022	dhacu	Effective Income Tax Rate Reconciliation Of Pipe Forward Contract Derivative EffectiveIncomeTaxRateReconciliationOfPipeForwardContractDerivative	-0.014
CY2023	dhacu	Effective Income Tax Rate Reconciliation Initial Fair Value Of Equity Line Of Credit EffectiveIncomeTaxRateReconciliationInitialFairValueOfEquityLineOfCredit	0.012
CY2023	dhacu	Effective Income Tax Rate Reconciliation Initial Fair Value Of Additional Bridge Promissory Note EffectiveIncomeTaxRateReconciliationInitialFairValueOfAdditionalBridgePromissoryNote	0.001
CY2023	dhacu	Effective Income Tax Rate Reconciliation Fair Value Changes Of Exchange Note EffectiveIncomeTaxRateReconciliationFairValueChangesOfExchangeNote	0.006
CY2023	dhacu	Effective Income Tax Rate Reconciliation Fair Value Changes In Equity Line Of Credits EffectiveIncomeTaxRateReconciliationFairValueChangesInEquityLineOfCredits	0.000
CY2023	dhacu	Effective Income Tax Rate Reconciliation Fair Value Changes Of Additional Bridge Promissory Note EffectiveIncomeTaxRateReconciliationFairValueChangesOfAdditionalBridgePromissoryNote	0.000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.253
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.293
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.061
CY2023	dhacu	Amount Withdrew From Trust Account AmountWithdrewFromTrustAccount	71436
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	6796063
CY2022	dhacu	Amount Withdrew From Trust Account AmountWithdrewFromTrustAccount	110472254
CY2022	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	10805877
CY2022Q4	dhacu	Pipe Forward Contract Derivative PipeForwardContractDerivative	170666
CY2022Q4	dhacu	Fair Value Liabilities Level1 To Level2 Transfer Amount FairValueLiabilitiesLevel1ToLevel2TransferAmount	0
CY2023Q4	dhacu	Fair Value Liabilities Level1 To Level2 Transfer Amount FairValueLiabilitiesLevel1ToLevel2TransferAmount	0

Files In Submission

Name	View Source	Status
0001104659-24-046607-index-headers.html	Edgar Link	pending
0001104659-24-046607-index.html	Edgar Link	pending
0001104659-24-046607.txt	Edgar Link	pending
0001104659-24-046607-xbrl.zip	Edgar Link	pending
dhacu-20231231.xsd	Edgar Link	pending
dhacu-20231231x10k.htm	Edgar Link	pending
dhacu-20231231xex31d1.htm	Edgar Link	pending
dhacu-20231231xex31d2.htm	Edgar Link	pending
dhacu-20231231xex32d1.htm	Edgar Link	pending
dhacu-20231231xex32d2.htm	Edgar Link	pending
dhacu-20231231xex4d5.htm	Edgar Link	pending
dhacu-20231231xex97d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
dhacu-20231231_def.xml	Edgar Link	unprocessable
dhacu-20231231_lab.xml	Edgar Link	unprocessable
dhacu-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
dhacu-20231231x10k_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dhacu-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VSEE
VSEE HEALTH, INC. Stock $vsee

2024 Q2 Form 10-K Financial Statement

#000110465924046607 Filed on April 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VSEE VSEE HEALTH, INC. Stock $vsee

2024 Q2 Form 10-K Financial Statement

#000110465924046607 Filed on April 12, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VSEE
VSEE HEALTH, INC. Stock $vsee